Status:
COMPLETED
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
Lead Sponsor:
AgelessRx
Conditions:
Aging
Eligibility:
All Genders
40-120 years
Brief Summary
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative effica...
Eligibility Criteria
Inclusion
- Receive AgelessRx's standard Rapamycin treatment protocol
- Opted to complete at least 1 blood draw at their local Quest Lab
Exclusion
- Not approved for current AgelessRx standard Rapamycin treatment
- History of uncontrolled disease
- Unable to complete at least 1 blood draw at their local Quest Lab
Key Trial Info
Start Date :
April 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT06550271
Start Date
April 25 2023
End Date
December 15 2023
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AgelessRx
Ann Arbor, Michigan, United States, 48104